Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 277

1.

Cytochrome P450 pharmacogenetics and cancer.

Rodriguez-Antona C, Ingelman-Sundberg M.

Oncogene. 2006 Mar 13;25(11):1679-91. Review.

PMID:
16550168
2.

Molecular genetics and epigenetics of the cytochrome P450 gene family and its relevance for cancer risk and treatment.

Rodriguez-Antona C, Gomez A, Karlgren M, Sim SC, Ingelman-Sundberg M.

Hum Genet. 2010 Jan;127(1):1-17. doi: 10.1007/s00439-009-0748-0. Review.

PMID:
19823875
3.

Cancer treatment and pharmacogenetics of cytochrome P450 enzymes.

van Schaik RH.

Invest New Drugs. 2005 Dec;23(6):513-22. Review.

PMID:
16267627
4.

Polymorphism of human cytochrome P450 enzymes and its clinical impact.

Zhou SF, Liu JP, Chowbay B.

Drug Metab Rev. 2009;41(2):89-295. doi: 10.1080/03602530902843483. Review.

PMID:
19514967
5.

Expression of cytochrome P450 in tumor tissues and its association with cancer development.

Oyama T, Kagawa N, Kunugita N, Kitagawa K, Ogawa M, Yamaguchi T, Suzuki R, Kinaga T, Yashima Y, Ozaki S, Isse T, Kim YD, Kim H, Kawamoto T.

Front Biosci. 2004 May 1;9:1967-76. Review.

PMID:
14977602
6.

Influence of cytochrome P450 polymorphisms on drug therapies: pharmacogenetic, pharmacoepigenetic and clinical aspects.

Ingelman-Sundberg M, Sim SC, Gomez A, Rodriguez-Antona C.

Pharmacol Ther. 2007 Dec;116(3):496-526. Review.

PMID:
18001838
7.

Genetic variability in susceptibility and response to toxicants.

Ingelman-Sundberg M.

Toxicol Lett. 2001 Mar 31;120(1-3):259-68. Review.

PMID:
11323184
8.

Cytochromes P450 and metabolism of xenobiotics.

Anzenbacher P, Anzenbacherová E.

Cell Mol Life Sci. 2001 May;58(5-6):737-47. Review.

PMID:
11437235
9.

Genetic polymorphism and toxicology--with emphasis on cytochrome p450.

Johansson I, Ingelman-Sundberg M.

Toxicol Sci. 2011 Mar;120(1):1-13. doi: 10.1093/toxsci/kfq374. Review.

10.

Cytochrome P450 and anticancer drugs.

Fujita K.

Curr Drug Metab. 2006 Jan;7(1):23-37. Review.

PMID:
16454691
11.

Cytochromes P450: decision-making tools for personalized therapeutics.

Murray M, Petrovic N.

Curr Opin Mol Ther. 2006 Dec;8(6):480-6. Review.

PMID:
17243482
12.

Cancer pharmacogenomics: achievements in basic research.

Nakajima M, Yokoi T.

Int J Clin Oncol. 2005 Feb;10(1):14-9. Review.

PMID:
15729595
13.

CYP450 pharmacogenetics for personalizing cancer therapy.

van Schaik RH.

Drug Resist Updat. 2008 Jun;11(3):77-98. doi: 10.1016/j.drup.2008.03.002. Review.

PMID:
18486526
15.

Implications of cytochrome P450 genetic polymorphisms on the toxicity of antitumor agents.

van Schaik RH.

Ther Drug Monit. 2004 Apr;26(2):236-40. Review.

PMID:
15228172
16.

Pharmacogenetics of the major polymorphic metabolizing enzymes.

Daly AK.

Fundam Clin Pharmacol. 2003 Feb;17(1):27-41. Review.

PMID:
12588628
17.

Genetic polymorphism of cytochromes P450: interethnic differences and relationship to incidence of lung cancer.

Ingelman-Sundberg M, Johansson I, Persson I, Yue QY, Dahl ML, Bertilsson L, Sjöqvist F.

Pharmacogenetics. 1992 Dec;2(6):264-71. Review.

PMID:
1306127
18.

Pharmacogenetics-guided dose modifications of antidepressants.

Seeringer A, Kirchheiner J.

Clin Lab Med. 2008 Dec;28(4):619-26. doi: 10.1016/j.cll.2008.05.006. Review.

PMID:
19059066
19.

Cytochrome P450s in the development of target-based anticancer drugs.

Purnapatre K, Khattar SK, Saini KS.

Cancer Lett. 2008 Jan 18;259(1):1-15. Review.

PMID:
18053638
20.

Role of xenobiotic metabolism in cancer: involvement of transcriptional and miRNA regulation of P450s.

Tamási V, Monostory K, Prough RA, Falus A.

Cell Mol Life Sci. 2011 Apr;68(7):1131-46. doi: 10.1007/s00018-010-0600-7. Review.

PMID:
21184128
Items per page

Supplemental Content

Support Center